NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment
Not Applicable
Terminated
- Conditions
- InfertilityIn-vitro Fertilization
- Interventions
- Registration Number
- NCT01298128
- Lead Sponsor
- University of Toronto
- Brief Summary
The newly designed contraceptive ring, Nuvaring has a lower total steroid dose, and medications are delivered locally. It has been proven to be as safe and effective as the combined OCP in ovarian suppression and preventing ovulation with fewer side effects due to minimal systemic absorption. Following a single vaginal insertion, steroid concentrations remain stable for up to 4 weeks. It is hypothesized that Nuvaring may, therefore lead to better compliance, tolerability and acceptance by patients requiring ovarian suppression prior to COH for IVF.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
- Patients less than 38 years of age.
- Healthy women starting their first IVF/ICSI cycle.
- No contraindication to Combined Oral Contraceptive (COC) use. Appendix 1
- Consent to randomization.
Exclusion Criteria
- Any contraindication to COC use.
- Hypersensitivity to Nuva ring or any of its components.
- Language barrier to consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NuvaRing NuvaRing NuvaRing for IVF pre-treatment Combined oral contraceptive pill marvelon OCP for IVF pre-treatment
- Primary Outcome Measures
Name Time Method Incidence of Side Effects of Oral Contraceptives Such as Abnormal Bleeding, Headache, Breast Discomfort, Bloating and Mood Swings (See Description) patients were followed for the duration of an in-vitro fertilization cycle- 2 months abnormal bleeding, intermittent bleeding, headache, breast discomfort, bloating, mood swings, nausea, vaginal discharge, vomitting, weight gain
- Secondary Outcome Measures
Name Time Method